Canada approves Alexion's enzyme replacement therapy Strensiq
This article was originally published in Scrip
Executive Summary
Following a first approval in Japan last month, Alexion Pharmaceutical's Strensiq (asfotase alfa) has now received market approval in Canada as a treatment for ultra-rare disease hypophosphatasia (HPP) – with a US decision to follow later this month.